Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
[This corrects the article DOI: 10.1371/journal.pone.0229231.].
Main Authors: | Wataru Kikushima, Atsushi Sugiyama, Seigo Yoneyama, Mio Matsubara, Yoshiko Fukuda, Ravi Parikh, Yoichi Sakurada |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0230505 |
Similar Items
-
Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
by: Kikushima Wataru, et al.
Published: (2020-01-01) -
Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
by: Yoshiko Fukuda, et al.
Published: (2020-07-01) -
Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results.
by: Mio Matsubara, et al.
Published: (2020-01-01) -
Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
by: Yoshiko Fukuda, et al.
Published: (2021-09-01) -
Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
by: Miura M, et al.
Published: (2013-08-01)